Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Exploring iNKT cell subset functionality to enhance adoptive cell therapy against non-small cell lung cancer

EF 2024-25

Résumé
The use of T cells for adoptive cell therapy (ACT) has revolutionized cancer treatment in recent years. However, challenges such as limited efficacy against solid tumors and immune-related side effects remain. Invariant Natural Killer T (iNKT) cells are promising candidates for ACT due to their potential for off-the-shelf use and their success in clinical trials targeting non-small cell lung cancer (NSCLC). Despite this, patient responses to iNKT cell-based ACT have varied, likely due to heterogeneity within the iNKT cell population. We hypothesize that specific iNKT cell subsets may be more effective in ACT. In particular, we postulate that CD57+ iNKT cells produce cytotoxic molecules that efficiently target and kill NSCLC cells, while CD4- CD62L+ iNKT cells possess central memory-like properties that could enhance long-term efficacy when combined with the CD57+ subset. To test this, I will first evaluate the functional capabilities of iNKT cell subsets in vitro, assessing the production of cytotoxic molecules and cytokines. I will then compare the cytotoxicity of different iNKT subsets (CD57+ and CD4- CD62L+) by co-culturing these cells with NSCLC cells and measuring tumor cell death over time. Finally, I will assess the in vivo efficacy of these subsets by intravenously injecting iNKT cells into immunodeficient mice engrafted with human NSCLC tumors. Mice will receive injections of CD57+, CD4- CD62L+, or a combination of both subsets, and tumor growth will be monitored over time to compare the effectiveness of these treatments. By investigating how different iNKT subsets target lung cancer cells, this research aims to optimize iNKT-based ACT and improve outcomes for NSCLC patients, providing novel avenues for lung cancer treatment.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
563443
Name
DiPonzio Milea
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Exploring iNKT cell subset functionality to enhance adoptive cell therapy against non-small cell lung cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adoptive Cell Therapy; Cancer Immunotherapy; Immunology; Invariant Natural Killer T Cell; Non-Small Cell Lung Cancer; Unconventional T Cell
Abstract
The use of T cells for adoptive cell therapy (ACT) has revolutionized cancer treatment in recent years. However, challenges such as limited efficacy against solid tumors and immune-related side effects remain. Invariant Natural Killer T (iNKT) cells are promising candidates for ACT due to their potential for off-the-shelf use and their success in clinical trials targeting non-small cell lung cancer (NSCLC). Despite this, patient responses to iNKT cell-based ACT have varied, likely due to heterogeneity within the iNKT cell population. We hypothesize that specific iNKT cell subsets may be more effective in ACT. In particular, we postulate that CD57+ iNKT cells produce cytotoxic molecules that efficiently target and kill NSCLC cells, while CD4- CD62L+ iNKT cells possess central memory-like properties that could enhance long-term efficacy when combined with the CD57+ subset. To test this, I will first evaluate the functional capabilities of iNKT cell subsets in vitro, assessing the production of cytotoxic molecules and cytokines. I will then compare the cytotoxicity of different iNKT subsets (CD57+ and CD4- CD62L+) by co-culturing these cells with NSCLC cells and measuring tumor cell death over time. Finally, I will assess the in vivo efficacy of these subsets by intravenously injecting iNKT cells into immunodeficient mice engrafted with human NSCLC tumors. Mice will receive injections of CD57+, CD4- CD62L+, or a combination of both subsets, and tumor growth will be monitored over time to compare the effectiveness of these treatments. By investigating how different iNKT subsets target lung cancer cells, this research aims to optimize iNKT-based ACT and improve outcomes for NSCLC patients, providing novel avenues for lung cancer treatment.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
DiPonzio, Milea
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~